CU20180152A7 - Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 - Google Patents
Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2Info
- Publication number
- CU20180152A7 CU20180152A7 CU2018000152A CU20180152A CU20180152A7 CU 20180152 A7 CU20180152 A7 CU 20180152A7 CU 2018000152 A CU2018000152 A CU 2018000152A CU 20180152 A CU20180152 A CU 20180152A CU 20180152 A7 CU20180152 A7 CU 20180152A7
- Authority
- CU
- Cuba
- Prior art keywords
- ilamino
- pyrimidin
- inhibitors
- lrrk2 inhibitors
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>La presente divulgación se refiere en general a los inhibidores de LRRK2 de fórmula I y Ia.</p> <p>ESPACIO PARA LAS FÓRMULAS</p> <p>o una de sus sales, análogos deuterados, profármacos, tautómeros, estereoisómeros farmacéuticamente aceptables o mezcla de sus estereoisómeros, así como métodos para su preparación, en el que dichos inhibidores son útiles en el tratamiento de una enfermedad neurodegenerativa, cáncer o una enfermedad inflamatoria.</p>
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662350876P | 2016-06-16 | 2016-06-16 | |
| US201662417151P | 2016-11-03 | 2016-11-03 | |
| US201762476581P | 2017-03-24 | 2017-03-24 | |
| US201762510711P | 2017-05-24 | 2017-05-24 | |
| PCT/US2017/037782 WO2017218843A1 (en) | 2016-06-16 | 2017-06-15 | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20180152A7 true CU20180152A7 (es) | 2019-09-04 |
| CU24605B1 CU24605B1 (es) | 2022-06-06 |
Family
ID=59216078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2018000152A CU24605B1 (es) | 2016-06-16 | 2017-06-15 | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 |
Country Status (37)
| Country | Link |
|---|---|
| US (7) | US20170362206A1 (es) |
| EP (3) | EP3472153B1 (es) |
| JP (1) | JP7004459B2 (es) |
| KR (3) | KR102553188B1 (es) |
| CN (2) | CN109311857B (es) |
| AU (3) | AU2017286653B2 (es) |
| CA (1) | CA3025672A1 (es) |
| CL (1) | CL2018003597A1 (es) |
| CO (1) | CO2018013585A2 (es) |
| CR (2) | CR20180592A (es) |
| CU (1) | CU24605B1 (es) |
| CY (1) | CY1124789T1 (es) |
| DK (1) | DK3998261T3 (es) |
| DO (3) | DOP2018000285A (es) |
| EC (1) | ECSP18092481A (es) |
| ES (2) | ES2900368T3 (es) |
| HR (1) | HRP20211923T1 (es) |
| HU (1) | HUE056678T2 (es) |
| IL (3) | IL299415B2 (es) |
| JO (1) | JOP20180113B1 (es) |
| LT (1) | LT3472153T (es) |
| MD (1) | MD3472153T2 (es) |
| MX (3) | MX392230B (es) |
| PE (2) | PE20240221A1 (es) |
| PH (1) | PH12018502427A1 (es) |
| PL (1) | PL3472153T3 (es) |
| PT (1) | PT3472153T (es) |
| RS (1) | RS62868B1 (es) |
| SA (2) | SA518400660B1 (es) |
| SG (2) | SG10201912632YA (es) |
| SI (1) | SI3472153T1 (es) |
| SM (1) | SMT202100699T1 (es) |
| TN (1) | TN2018000422A1 (es) |
| TW (1) | TWI786049B (es) |
| UA (1) | UA126231C2 (es) |
| WO (1) | WO2017218843A1 (es) |
| ZA (1) | ZA201900229B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| SI3472153T1 (sl) | 2016-06-16 | 2022-01-31 | Denali Therapeutics Inc. | Pirimidin-2-ilamino-1H-pirazoli kot zaviralci LRRK2 za uporabo pri zdravljenju nevrodegenerativnih motenj |
| PE20210157A1 (es) | 2017-11-21 | 2021-01-26 | Denali Therapeutics Inc | Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion |
| US11834438B2 (en) | 2017-12-20 | 2023-12-05 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
| KR20190131981A (ko) * | 2018-05-18 | 2019-11-27 | 재단법인 대구경북첨단의료산업진흥재단 | 외상성 뇌손상 또는 뇌졸중의 예방 또는 치료용 약학적 조성물 |
| AR118641A1 (es) * | 2019-04-11 | 2021-10-20 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| BR112021024194A2 (pt) * | 2019-05-31 | 2022-01-11 | Denali Therapeutics Inc | Formulação de liberação modificada de um composto de pirimidinilamino-pirazol e métodos de tratamento |
| EP3769768A1 (en) | 2019-07-23 | 2021-01-27 | Consejo Superior de Investigaciones Cientificas (CSIC) | Compounds useful for the treatment of parkinson s disease |
| AR120324A1 (es) * | 2019-10-29 | 2022-02-09 | Biogen Ma Inc | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica |
| KR102342803B1 (ko) | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
| JP7671775B2 (ja) | 2020-03-23 | 2025-05-02 | ファニン ファーマシューティカル カンパニー リミテッド | 新規なピリミジン誘導体及びこれを含む神経退行性疾患及び癌の予防又は治療用組成物 |
| WO2022074093A1 (en) * | 2020-10-07 | 2022-04-14 | Alzprotect | Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders |
| KR20230091150A (ko) * | 2020-10-29 | 2023-06-22 | 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 | 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도 |
| KR20230097093A (ko) | 2020-10-29 | 2023-06-30 | 머크 샤프 앤드 돔 엘엘씨 | Lrrk2 억제제로서의 n-연결된 이소퀴놀린 아미드, 제약 조성물 및 그의 용도 |
| EP4329763A4 (en) * | 2021-04-30 | 2025-03-05 | Denali Therapeutics Inc. | Methods for treating and monitoring parkinson's disease |
| TW202330549A (zh) | 2021-10-27 | 2023-08-01 | 丹麥商Ｈ 朗德貝克公司 | Lrrk2抑制劑 |
| EP4450505A4 (en) | 2021-12-15 | 2025-07-02 | Whan In Pharmaceutical Co Ltd | MACROCYCLIC PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE AND CONTAINING THIS DERIVATIVE AS ACTIVE INGREDIENT |
| CN117624185B (zh) * | 2022-08-23 | 2025-12-05 | 长春金赛药业有限责任公司 | Lrrk2抑制剂化合物、药物组合物及其制备方法和应用 |
| WO2024056775A1 (en) | 2022-09-15 | 2024-03-21 | H. Lundbeck A/S | Macrocyclic leucine-rich repeat kinase 2 (lrrk2) inhibitors |
| WO2024097394A1 (en) | 2022-11-03 | 2024-05-10 | Denali Therapeutics Inc. | Solid and co-crystal forms of a pyrimidine triazole compound |
| CN115894456A (zh) * | 2022-11-13 | 2023-04-04 | 药康众拓(江苏)医药科技有限公司 | 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途 |
| WO2024112746A1 (en) | 2022-11-22 | 2024-05-30 | Denali Therapeutics Inc. | Processes and intermediates for the preparation of a pyrimidine aminopyrazole compound |
| CN115819405A (zh) * | 2022-12-20 | 2023-03-21 | 沪渝人工智能研究院 | 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用 |
| CN119968373A (zh) * | 2023-09-07 | 2025-05-09 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其制备方法 |
| WO2026002197A1 (zh) * | 2024-06-28 | 2026-01-02 | 成都康弘药业集团股份有限公司 | 一种治疗或预防lrrk2介导的疾病的化合物 |
| CN118878521B (zh) * | 2024-09-26 | 2025-02-14 | 苏州美诺医药科技有限公司 | 一种lrrk2抑制剂的制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3127900A (en) | 1998-12-23 | 2000-07-31 | Du Pont Pharmaceuticals Company | Thrombin or factor xa inhibitors |
| WO2003076658A2 (en) | 2002-03-08 | 2003-09-18 | Decode Genetics Ehf. | A susceptibility gene for late-onset idiopathic parkinson's disease |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| AR049418A1 (es) | 2004-02-27 | 2006-08-02 | Bayer Pharmaceuticals Corp | Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. |
| AU2005322855B2 (en) | 2004-12-30 | 2012-09-20 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
| US20090247554A1 (en) | 2006-03-30 | 2009-10-01 | Takeda San Diego, Inc. | Kinase inhibitors |
| KR20090019848A (ko) | 2006-06-20 | 2009-02-25 | 노파르티스 아게 | 알쯔하이머 병의 진행에 대한 생체마커 |
| US7947698B2 (en) | 2007-03-23 | 2011-05-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| EP2146969A1 (en) | 2007-04-19 | 2010-01-27 | Novartis Ag | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 |
| CN101679378A (zh) | 2007-05-02 | 2010-03-24 | 沃泰克斯药物股份有限公司 | 用作激酶抑制剂的噻唑和吡唑 |
| AU2008257044A1 (en) | 2007-05-24 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| WO2009032694A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| AR075713A1 (es) | 2009-03-03 | 2011-04-20 | Du Pont | Pirazoles fungicidas |
| WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| JP5740409B2 (ja) | 2009-11-13 | 2015-06-24 | ジェノスコ | キナーゼ阻害剤 |
| GB201008134D0 (en) | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| HUE029196T2 (en) | 2010-06-04 | 2017-02-28 | Hoffmann La Roche | Aminoprimidine derivatives as LRRK2 modulators |
| US8637529B2 (en) | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
| WO2012058193A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Leucine-rich repeat kinase enzyme activity |
| SG189043A1 (en) * | 2010-11-10 | 2013-05-31 | Hoffmann La Roche | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| CN103348243A (zh) | 2010-11-30 | 2013-10-09 | 基因泰克公司 | Lrrk2的分析方法和生物标记物 |
| CA2841416A1 (en) | 2011-06-15 | 2012-12-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| CN103781780B (zh) | 2011-07-28 | 2015-11-25 | 赛尔佐姆有限公司 | 作为jak抑制剂的杂环基嘧啶类似物 |
| MD20140023A2 (ro) | 2011-09-22 | 2014-06-30 | Pfizer Inc. | Derivaţi de pirolpirimidină şi purină |
| MX349556B (es) | 2011-11-29 | 2017-08-03 | Genentech Inc | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). |
| US8791130B2 (en) | 2011-11-29 | 2014-07-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| CA2850594C (en) | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
| EP2785381B1 (en) | 2011-11-30 | 2016-05-18 | F.Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
| WO2013126283A1 (en) | 2012-02-20 | 2013-08-29 | E. I. Du Pont De Nemours And Company | Fungicidal pyrazoles |
| DK3321262T3 (da) | 2012-03-01 | 2021-01-25 | Array Biopharma Inc | Serin-/threoninkinasehæmmere |
| CN104271569B (zh) * | 2012-05-03 | 2016-08-24 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的吡唑氨基嘧啶衍生物 |
| EP2844658B1 (en) * | 2012-05-03 | 2019-03-20 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| CN104936949A (zh) | 2013-01-25 | 2015-09-23 | 百时美施贵宝公司 | 用于治疗丙型肝炎的squaric衍生物 |
| EP3010908A1 (en) | 2013-02-20 | 2016-04-27 | E. I. du Pont de Nemours and Company | Fungicidal pyrazoles |
| WO2014135245A1 (en) | 2013-03-05 | 2014-09-12 | Merck Patent Gmbh | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| EP3670515B1 (en) | 2013-03-15 | 2024-03-06 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| EP2968995B1 (en) | 2013-03-15 | 2018-05-09 | Elan Pharmaceuticals LLC | Inhibitors of lrrk2 kinase activity |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| EP2994465B1 (en) | 2013-05-10 | 2018-08-15 | Karus Therapeutics Limited | Novel histone deacetylase inhibitors |
| US10087186B2 (en) | 2014-01-29 | 2018-10-02 | Glaxosmithkline Intellectual Property Development Limited | Compounds as LRRK2 kinase inhibitors |
| US9580430B2 (en) | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| WO2015148868A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| JP6684780B2 (ja) | 2014-08-25 | 2020-04-22 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 新規ｕｌｋ１阻害剤およびそれを使用する方法 |
| CN105461694B (zh) | 2014-09-27 | 2019-05-24 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| PL3227297T3 (pl) | 2014-12-05 | 2021-10-25 | Array Biopharma, Inc. | 4,6 podstawione-pyrazolo[1,5-a]pirazyny jako inhibitory kinaz janusowych |
| JP2018510155A (ja) | 2015-03-19 | 2018-04-12 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ | 殺菌・殺カビ性ピラゾール |
| JP2018135268A (ja) | 2015-06-05 | 2018-08-30 | 大日本住友製薬株式会社 | 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩 |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN108137586B (zh) | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 |
| US9840710B2 (en) | 2015-11-18 | 2017-12-12 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| WO2017100703A1 (en) | 2015-12-10 | 2017-06-15 | Colin Combs | Ems analogues of lyn/src-tyrosine kinase inhibitors |
| CN108934162A (zh) | 2015-12-16 | 2018-12-04 | 南方研究所 | 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法 |
| IL287136B2 (en) * | 2016-02-05 | 2023-09-01 | Denali Therapeutics Inc | Receptor inhibitors - interacting with protein kinase 1 |
| SI3472153T1 (sl) | 2016-06-16 | 2022-01-31 | Denali Therapeutics Inc. | Pirimidin-2-ilamino-1H-pirazoli kot zaviralci LRRK2 za uporabo pri zdravljenju nevrodegenerativnih motenj |
| WO2018217946A1 (en) | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
-
2017
- 2017-06-15 SI SI201731005T patent/SI3472153T1/sl unknown
- 2017-06-15 IL IL299415A patent/IL299415B2/en unknown
- 2017-06-15 CA CA3025672A patent/CA3025672A1/en active Pending
- 2017-06-15 SM SM20210699T patent/SMT202100699T1/it unknown
- 2017-06-15 KR KR1020197000749A patent/KR102553188B1/ko active Active
- 2017-06-15 CR CR20180592A patent/CR20180592A/es unknown
- 2017-06-15 JP JP2018565694A patent/JP7004459B2/ja active Active
- 2017-06-15 WO PCT/US2017/037782 patent/WO2017218843A1/en not_active Ceased
- 2017-06-15 SG SG10201912632YA patent/SG10201912632YA/en unknown
- 2017-06-15 US US15/624,566 patent/US20170362206A1/en not_active Abandoned
- 2017-06-15 SG SG11201810579YA patent/SG11201810579YA/en unknown
- 2017-06-15 CN CN201780036925.3A patent/CN109311857B/zh active Active
- 2017-06-15 IL IL299412A patent/IL299412B2/en unknown
- 2017-06-15 PE PE2023001478A patent/PE20240221A1/es unknown
- 2017-06-15 PE PE2018003221A patent/PE20190395A1/es unknown
- 2017-06-15 CU CU2018000152A patent/CU24605B1/es unknown
- 2017-06-15 CN CN202111282850.1A patent/CN114315819A/zh active Pending
- 2017-06-15 PL PL17733306T patent/PL3472153T3/pl unknown
- 2017-06-15 DK DK21198102.2T patent/DK3998261T3/da active
- 2017-06-15 EP EP17733306.9A patent/EP3472153B1/en active Active
- 2017-06-15 JO JOP/2018/0113A patent/JOP20180113B1/ar active
- 2017-06-15 HU HUE17733306A patent/HUE056678T2/hu unknown
- 2017-06-15 IL IL263484A patent/IL263484B2/en unknown
- 2017-06-15 HR HRP20211923TT patent/HRP20211923T1/hr unknown
- 2017-06-15 KR KR1020247029993A patent/KR102843750B1/ko active Active
- 2017-06-15 RS RS20211513A patent/RS62868B1/sr unknown
- 2017-06-15 LT LTEPPCT/US2017/037782T patent/LT3472153T/lt unknown
- 2017-06-15 MX MX2018015630A patent/MX392230B/es unknown
- 2017-06-15 EP EP25174508.9A patent/EP4635570A3/en active Pending
- 2017-06-15 ES ES17733306T patent/ES2900368T3/es active Active
- 2017-06-15 EP EP21198102.2A patent/EP3998261B1/en active Active
- 2017-06-15 KR KR1020237022665A patent/KR102705724B1/ko active Active
- 2017-06-15 CR CR20220182A patent/CR20220182A/es unknown
- 2017-06-15 MD MDE20190504T patent/MD3472153T2/ro unknown
- 2017-06-15 PT PT177333069T patent/PT3472153T/pt unknown
- 2017-06-15 ES ES21198102T patent/ES3036953T3/es active Active
- 2017-06-15 TN TNP/2018/000422A patent/TN2018000422A1/en unknown
- 2017-06-15 UA UAA201812165A patent/UA126231C2/uk unknown
- 2017-06-15 AU AU2017286653A patent/AU2017286653B2/en active Active
- 2017-06-16 TW TW106120263A patent/TWI786049B/zh active
- 2017-10-25 US US15/793,882 patent/US9932325B2/en active Active
-
2018
- 2018-03-21 US US15/927,920 patent/US10590114B2/en active Active
- 2018-11-19 PH PH12018502427A patent/PH12018502427A1/en unknown
- 2018-12-13 SA SA518400660A patent/SA518400660B1/ar unknown
- 2018-12-13 DO DO2018000285A patent/DOP2018000285A/es unknown
- 2018-12-13 MX MX2022005610A patent/MX2022005610A/es unknown
- 2018-12-13 MX MX2021010304A patent/MX2021010304A/es unknown
- 2018-12-13 SA SA521430638A patent/SA521430638B1/ar unknown
- 2018-12-14 EC ECSENADI201892481A patent/ECSP18092481A/es unknown
- 2018-12-14 CO CONC2018/0013585A patent/CO2018013585A2/es unknown
- 2018-12-14 CL CL2018003597A patent/CL2018003597A1/es unknown
-
2019
- 2019-01-14 ZA ZA2019/00229A patent/ZA201900229B/en unknown
-
2020
- 2020-03-13 US US16/818,745 patent/US11111235B2/en active Active
-
2021
- 2021-08-13 US US17/401,833 patent/US11591316B2/en active Active
- 2021-12-14 CY CY20211101098T patent/CY1124789T1/el unknown
-
2022
- 2022-04-08 AU AU2022202372A patent/AU2022202372B2/en active Active
- 2022-04-25 DO DO2022000088A patent/DOP2022000088A/es unknown
-
2023
- 2023-01-19 US US18/099,082 patent/US11834439B2/en active Active
- 2023-04-17 DO DO2023000077A patent/DOP2023000077A/es unknown
-
2024
- 2024-06-14 US US18/744,133 patent/US20250034119A1/en active Pending
- 2024-07-03 AU AU2024204621A patent/AU2024204621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| ECSP19011216A (es) | Inhibidores de piridopyrimdinona cdk2/4/6 | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| DOP2016000140A (es) | Inhibidores de syk | |
| CL2017000712A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| CR20180232A (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| MX2018005725A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer. | |
| MX2016001304A (es) | Polimorfo de inhibidores de syk. | |
| SV2016005294A (es) | 2-amino-6-metil-4,4a,5,6-tetrahidropirano(3,4-d)(1,3)tiazin-8a(8h)-il-1,3-tiazol-4-ilamidas | |
| CL2017000820A1 (es) | Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos | |
| MX2020004283A (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| UY33885A (es) | Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes | |
| CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
| CO2017000011A2 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| CU20160157A7 (es) | Derivados de diheterociclo enlazado a cicloalquilo |